No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
5658 |
4. Check minimum number of events
Min. number of events
3
|
5658 |
5. Include endpointsNone |
5658 |
6. Filter based on genotype QC (FinnGen only) |
5459 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
First used in FinnGen datafreeze
DF5
Similar endpoints
↥List of similar endpoints to
Biological medication for rheuma
based on the number of shared cases.
Similar with more cases:
- ILD medications: immunosuppressive drugs
- ILD medications
- Any reimbursement code in KELA
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 27308 | 15324 | 11931 |
| Only index persons | 26669 | 14962 | 11707 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.39 | 0.44 | 0.33 |
| Only index persons | 0.50 | 0.55 | 0.45 |
| Median age at first event (years) | |||
| Whole population | 45.20 | 45.96 | 44.26 |
| Only index persons | 45.68 | 46.51 | 44.62 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 5459 | 3368 | 2091 |
| Unadjusted period prevalence (%) | 1.22 | 1.32 | 1.05 |
| Median age at first event (years) | 48.28 | 48.28 | 48.27 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Mortality – FinRegistry
↥Association
Association between endpoint RX_RHEUMA_BIOLOGICAL and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| RX_RHEUMA_BIOLOGICAL | 1.215 [1.03, 1.43] | 0.02 |
| Birth year | 0.995 [0.99, 1.0] | 0.23 |
During the follow-up period (1.1.1998 — 31.12.2019), 412 out of 12676 females with RX_RHEUMA_BIOLOGICAL died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| RX_RHEUMA_BIOLOGICAL | 1.05 [0.89, 1.24] | 0.563 |
| Birth year | 0.989 [0.98, 1.0] | 0.018 |
During the follow-up period (1.1.1998 — 31.12.2019), 404 out of 9858 males with RX_RHEUMA_BIOLOGICAL died.
Mortality risk
Mortality risk for people of age
years, who have RX_RHEUMA_BIOLOGICAL.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.084% | 0.15% |
| 5 | 0.616% | 1.265% |
| 10 | 1.714% | 3.156% |
| 15 | 3.288% | 6.052% |
| 20 | 6.051% | 10.247% |
Relationships between endpoints
↥Index endpoint: RX_RHEUMA_BIOLOGICAL – Biological medication for rheuma
GWS hits: 4
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data